| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ALK1 |
| Uniprot No | P37023 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-118aa |
| 氨基酸序列 | MTLGSPRKGL LMLLMALVTQ GDPVKPSRGP LVTCTCESPH CKGPTCRGAW CTVVLVREEG RHPQEHRGCG NLHRELCRGR PTEFVNHYCC DSHLCNHNVS LVLEATQPPS EQPGTDGQ |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"ALK1 as an emerging therapeutic target in cancer"**
*作者：Cunha SI, Pietras K*
摘要：探讨了ALK1在肿瘤血管生成中的作用，发现重组ALK1蛋白通过调节内皮细胞信号抑制肿瘤生长，提示其作为抗血管生成治疗的潜力。
2. **"A role for ALK1 in HHT-associated vascular dysplasia"**
*作者：Lebrin F, et al.*
摘要：研究重组ALK1蛋白在遗传性出血性毛细血管扩张症(HHT)中的功能，证明其通过调控BMP9/Smad通路修复异常血管结构，为治疗提供依据。
3. **"ALK1-Fc fusion protein inhibits tumor angiogenesis in preclinical models"**
*作者：Mitchell D, et al.*
摘要：报道了一种ALK1-Fc重组融合蛋白的开发，通过阻断BMP9/10配体显著抑制小鼠模型中肿瘤血管生成和转移。
4. **"ALK1 loss leads to defective yolk sac angiogenesis in mouse embryos"**
*作者：Oh SP, Urness LD*
摘要：利用基因敲除模型揭示ALK1缺失导致胚胎血管发育异常，重组ALK1蛋白可部分挽救表型，强调其在早期血管形成中的关键作用。
(注：上述为模拟文献示例，实际引用需核实具体论文信息。)
**Background of ALK1 Recombinant Protein**
Activin receptor-like kinase 1 (ALK1), also known as ACVRL1. is a type I transmembrane serine/threonine kinase receptor belonging to the TGF-β (transforming growth factor-beta) superfamily. It plays a critical role in angiogenesis, vascular development, and endothelial cell function. ALK1 is predominantly expressed in endothelial cells, where it binds ligands such as BMP9 (bone morphogenetic protein 9) and BMP10. initiating downstream signaling cascades via SMAD1/5/8 phosphorylation. This pathway regulates cellular responses, including proliferation, migration, and vascular remodeling.
Mutations in the *ACVRL1* gene are linked to hereditary hemorrhagic telangiectasia type 2 (HHT2), a genetic disorder characterized by abnormal blood vessel formation, leading to arteriovenous malformations and recurrent bleeding. This highlights ALK1's essential role in maintaining vascular integrity.
Recombinant ALK1 protein is engineered to mimic the extracellular ligand-binding domain or full-length receptor for research and therapeutic applications. Produced using mammalian or insect cell systems to ensure proper post-translational modifications, it serves as a tool to study ALK1-mediated signaling mechanisms or as a decoy receptor to modulate pathway activity. In therapeutics, recombinant ALK1 has been explored to inhibit pathological angiogenesis in cancers or ocular diseases. For instance, ALK1-Fc fusion proteins can sequester BMP9/10. blocking pro-angiogenic signals.
Overall, ALK1 recombinant protein is pivotal in advancing understanding of vascular biology and developing targeted therapies for angiogenesis-related disorders.
×
